A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures
The purpose of this study is to evaluate the efficacy and safety of topiramate as add-on
 therapy in epilepsy patients with difficult to treat, partial-onset seizures who are taking
 one or two standard anti-epileptic drugs.
Epilepsy is characterized by seizures, which are abnormal electrical discharges in the brain
 that temporarily disrupt normal brain function. Seizures are classified as "generalized,"
 originating in both sides of the brain simultaneously, or "partial-onset," starting in one
 area of the brain. Antiepilepsy medications, such as topiramate, are selected based on
 seizure type. This is a double-blind, placebo-controlled study in adult patients with
 difficult to treat partial epilepsy that includes a baseline phase and a treatment phase.
 During the baseline phase (8 weeks duration), patients receive their one or two standard
 antiepileptic drugs (AEDs), such as phenytoin, carbamazepine, phenobarbital, primidone, or
 valproic acid. Patients who continue to have seizures during treatment with standard AEDs
 proceed into the double-blind treatment phase. Patients then receive topiramate or placebo at
 a dosage of 100-milligrams (mg) once daily, increasing gradually over 5 weeks to 4 tablets
 twice daily (800 mg/day) or maximum tolerated dose, and maintained on that dose for 8 weeks
 (13 weeks is the total duration of the double-blind phase), while continuing on their
 standard AED regimen. Assessments of effectiveness include the percent reduction in the
 average monthly seizure rate, percent of patients responding to treatment (having equal to or
 greater than 50% reduction in seizure rate), and the patient's and investigator's global
 assessments of medication at end of study. Safety assessments include the incidence of
 adverse events throughout the study, clinical laboratory tests (hematology, serum chemistry,
 urinalysis), neurologic examinations, and vital sign measurements (blood pressure, pulse,
 temperature) weekly during the treatment phase. The study hypothesis is that topiramate,
 taken as add-on therapy to treatment with AEDs, will significantly reduce seizure frequency,
 compared with placebo, in patients with refractory partial epilepsy: that is, in patients who
 continue to have seizures despite treatment with a first-line AEDs. In addition, it is
 hypothesized that topiramate will be well tolerated. Topiramate, 100 mg oral tablets, or
 matching placebo tablets. Dosage begins at 100 mg once daily and increases gradually over 5
 weeks to 4 tablets twice daily (800 mg/day, maximum) or maximum tolerated dose for an
 additional 8 weeks. Doses may be increased or decreased at investigator's discretion.
Inclusion Criteria:

 -  History of simple or complex partial epilepsy that has been documented or witnessed

 -  an electroencephalogram (EEG) during the preceding 5 years that has a pattern
 consistent with the diagnosis of partial epilepsy

 -  during an 8-week baseline phase, patient must have at least 8 partial seizures while
 maintaining therapeutic levels of antiepileptic drugs (AEDs) and have no more than one
 seizure-free interval of up to 3 weeks

 -  and no seizure-free interval longer than 3 weeks

 -  good physical health.

 Exclusion Criteria:

 -  Patients having solely generalized seizures or lacking documentation of partial
 epilepsy

 -  patients with generalized tonic-clonic seizures or other generalized epilepsies in the
 absence of an EEG consistent with partial epilepsy

 -  generalized seizures, which are defined by the EEG wave pattern

 -  seizures that lack an abnormal pulsation pattern on EEG

 -  females who are capable of having children